- Home
- SR vs MIRM Comparison
SR vs MIRM Comparison
Compare SR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SR | MIRM |
|---|---|---|
| Founded | 1857 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SR | MIRM |
|---|---|---|
| Price | $92.17 | $96.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $90.13 | ★ $115.33 |
| AVG Volume (30 Days) | 291.0K | ★ 805.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $6.93 | $26.22 |
| Revenue Next Year | $5.02 | $22.04 |
| P/E Ratio | $19.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.24 | $38.22 |
| 52 Week High | $95.31 | $109.28 |
Technical Indicators
Market Signals| Indicator | SR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 54.06 |
| Support Level | $88.86 | $85.35 |
| Resistance Level | $94.27 | $98.03 |
| Average True Range (ATR) | 1.80 | 3.68 |
| MACD | -0.03 | 0.61 |
| Stochastic Oscillator | 49.58 | 72.93 |
Price Performance
Historical ComparisonAbout SR Spire Inc.
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.